During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.” But before the 60-second spot was ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care ...

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.